help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikolaizik, W. H.
Right arrow Articles by Crameri, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikolaizik, W. H.
Right arrow Articles by Crameri, R.

Am. J. Respir. Crit. Care Med., Volume 165, Number 7, April 2002, 916-921

Intracutaneous Tests with Recombinant Allergens in Cystic Fibrosis Patients with Allergic Bronchopulmonary Aspergillosis and Aspergillus Allergy

Wilfried H. Nikolaizik, Michael Weichel, Kurt Blaser, and Reto Crameri

University Hospital, Essen, Germany; and Swiss Institute of Allergy and Asthma Research, Davos, Switzerland

Allergic bronchopulmonary aspergillosis (ABPA), an intensive inflammatory reaction to Aspergillus fumigatus, can cause irreversible lung damage in patients with cystic fibrosis (CF). The aim of this study was to assess if intracutaneous testing with recombinant A. fumigatus allergens (rAsp f   ) allowed a reliable diagnosis of ABPA. Fifty patients with CF were tested, 12 suffering from ABPA, 21 with allergy to A. fumigatus, and 17 CF control patients not sensitized to A. fumigatus. All patients with ABPA reacted to at least one of the two intracellular A. fumigatus allergens rAsp f 4, a 30-kD protein of unknown biologic function, and rAsp f 6, a 23-kD manganese superoxide dismutase, at a concentration of 10-2 µg/ml. The intracutaneous tests were negative or only marginally positive in the patients with allergy to A. fumigatus and completely negative in the CF control patients. The differential responses to the recombinant A. fumigatus allergens were in perfect agreement with our previous serologic results, so that rAsp f 4 and rAsp f 6 can be considered specific markers for ABPA. Early diagnosis of the disease might help to prevent irreversible lung damage and minimize possible steroid-mediated side effects as a consequence of an optimized control of the disease.




This article has been cited by other articles:


Home page
 ChestHome page
R. Agarwal
Allergic Bronchopulmonary Aspergillosis
Chest, March 1, 2009; 135(3): 805 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Giavina-Bianchi, E. Oliveira, and J. Kalil
Specific IgE against Recombinant Allergens in Allergic Bronchopulmonary Aspergillosis
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 967a - 967a.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Kraemer, N. Delosea, P. Ballinari, S. Gallati, and R. Crameri
Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1211 - 1220.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. Hartl, P. Latzin, G. Zissel, M. Krane, S. Krauss-Etschmann, and M. Griese
Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1370 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 333 - 344.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  Red In Translatin